Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an announcement.
MicroPort CardioFlow Medtech Corp. announced that its Alwide® Plus balloon catheter has received CE Mark approval, signifying compliance with European health and safety standards. This approval not only enhances the company’s product offerings in the European market but also supports its overseas revenue growth and commercialization efforts for other products like the VitaFlow Liberty® system. The approval highlights the company’s strong technological capabilities and strategic positioning in the global high-end medical device market.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corp. is a company in the medical device industry, focusing on developing advanced products for structural heart disease treatment. Its primary products include surgical accessories and systems for transcatheter aortic valve implantation (TAVI), with a significant focus on the European market.
Average Trading Volume: 11,270,277
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.57B
See more insights into 2160 stock on TipRanks’ Stock Analysis page.